[HTML][HTML] Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna
A Brault, C Tran-Kiem, C Couteaux, V Olié… - The Lancet Regional …, 2023 - thelancet.com
Summary Background Ending Zero-COVID is challenging, particularly when vaccine
coverage is low. Considering Wallis and Futuna, a French Zero-COVID territory affected by …
coverage is low. Considering Wallis and Futuna, a French Zero-COVID territory affected by …
Disease progression of hospitalized elderly patients with omicron BA. 2 treated with molnupiravir
Y Liu, L Ge, S Fan, A Xu, X Wang, X Dong, M Xu… - Infectious Diseases and …, 2022 - Springer
Introduction The efficacy of molnupiravir (MLN) on Omicron sublineages is limited. We
investigated the effectiveness of MLN in older adults diagnosed with Omicron BA. 2 …
investigated the effectiveness of MLN in older adults diagnosed with Omicron BA. 2 …
[HTML][HTML] Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations
H Soares, ML Baniecki, R Cardin, H Leister-Tebbe… - 2022 - europepmc.org
Nirmatrelvir-ritonavir was developed for the treatment of COVID-19 and has shown efficacy
in a Phase 2/3 study of high risk patients (EPIC-HR1). Monitoring for the emergence of viral …
in a Phase 2/3 study of high risk patients (EPIC-HR1). Monitoring for the emergence of viral …
New therapeutic options in mild moderate COVID-19 outpatients
C Ucciferri, A Di Gasbarro, P Borrelli, M Di Nicola… - Microorganisms, 2022 - mdpi.com
Background: In recent years, the therapeutic options for COVID have significantly improved;
however, the therapies are expensive with restricted access to drugs, and expeditious and …
however, the therapies are expensive with restricted access to drugs, and expeditious and …
A randomised-controlled phase 2 trial of molnupiravir in unvaccinated and vaccinated individuals with early SARS-CoV-2
SH Khoo, R FitzGerald, G Saunders, C Middleton… - MedRxiv, 2022 - medrxiv.org
Background Molnupiravir was licensed for treating high-risk patients with COVID-19 based
on data from unvaccinated adults. AGILE CST-2 (NCT04746183) Phase II reports safety and …
on data from unvaccinated adults. AGILE CST-2 (NCT04746183) Phase II reports safety and …
[HTML][HTML] An IgM-like Inhalable ACE2 fusion protein broadly neutralizes SARS-CoV-2
W Li, J Liu, F Mao, J Chen, S Lu, Y Qi, Y Sun, L Fang… - 2022 - europepmc.org
Many of the currently available COVID-19 vaccines and therapeutics are not effective
against newly emerged SARS-CoV-2 variants. Here, we developed the metallo-enzyme …
against newly emerged SARS-CoV-2 variants. Here, we developed the metallo-enzyme …
Determining population-level allocation strategies for COVID-19 treatments in the United States using a quantitative framework, a case study using nirmatrelvir …
Background New COVID-19 medications force decision makers to weigh limited evidence of
efficacy and cost in determining which patient populations to target for treatment. A case in …
efficacy and cost in determining which patient populations to target for treatment. A case in …
Molnupiravir for the Treatment of Coronavirus Disease 2019: A Systematic Review With Meta-Analysis of 12,451 Patients
2. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse
drug reactions. Clin Pharmacol Ther. 1981; 30: 239-245. 3. Greene HL, Graham EL, Werner …
drug reactions. Clin Pharmacol Ther. 1981; 30: 239-245. 3. Greene HL, Graham EL, Werner …
[PDF][PDF] COVID-19: traitements actuels à l'ère de la vaccination
N Dauby - Rev Med Brux, 2022 - amub-ulb.be
RÉSUMÉ D'une pneumonie virale d'origine inconnue à une maladie multi-systémique hyper-
inflammatoire, l'évolution des connaissances sur l'infection à SARS-CoV-2 et la maladie à …
inflammatoire, l'évolution des connaissances sur l'infection à SARS-CoV-2 et la maladie à …